Ignacio Rodriguez, MD
Interventional Pain Medicine · Hialeah, FLNPI 1386600708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $349 and has fallen 92.5% since, to $26 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in FL, where the typical reported total is $4,625.
Across 63 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$279
- Scilex Pharmaceuticals Inc.$230
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$167
- Collegium Pharmaceutical, Inc.$113
- Pfizer$91
- Pacira Therapeutics, Inc.$54
- plus $280 from 10 others
Across 21 payments — averaging $17,799 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$208K
- Seikagaku Corporation$166K
What the payments were for
- Food & beverage$1,214100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 14 | $279 |
| Scilex Pharmaceuticals Inc. | 12 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $167 |
| Collegium Pharmaceutical, Inc. | 5 | $113 |
| Pfizer | 5 | $91 |
| Pacira Therapeutics, Inc. | 2 | $54 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
| AstraZeneca | 3 | $41 |
| Forte Bio-pharma LLC | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Protega Pharmaceutials Inc | 1 | $26 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Virtus Pharmaceuticals LLC | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Electronic Waveform Lab, Inc. | 2 | $16 |
How this compares
$1,214 in reported general payments places this provider in the 25th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 28 | $32,336 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 940 | $28,890 |
| MovantikNaloxegol Oxalate | 29 | $11,629 |
| Lidocaine | 98 | $9,350 |
| Diclofenac Sodium | 400 | $5,135 |
| Gabapentin | 502 | $3,843 |
| Celecoxib | 56 | $3,554 |
| Fentanyl | 37 | $3,352 |
| Oxycodone Hcl | 117 | $3,121 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 136 | $2,484 |
| Tramadol Hcl | 313 | $2,044 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 73 | $1,626 |
| Morphine Sulfate ErMorphine Sulfate | 43 | $1,443 |
| Pregabalin | 111 | $1,321 |
| Naloxone Hcl | 18 | $1,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $279 | $11,62929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Hialeah
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.